Ranolazine does not typically affect blood pressure, so it can be combined with most antihypertensives. However, because it may interact with drugs that influence the CYP3A4 enzyme or prolong the QT interval, a pharmacist or cardiologist should review the full medication list.
A sudden increase in heart rate could indicate an arrhythmia. Seek medical attention promptly, especially if accompanied by dizziness, chest discomfort, or fainting.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and be aware of any country-specific import restrictions for prescription drugs.
In the UK the 500 mg tablets are typically white, round, and bear a specific imprint code (e.g., “R500”). The 1000 mg tablets are usually blue, round, with a different imprint. Always verify the imprint against the pharmacy label.
No. Ranexa tablets must be swallowed whole. Crushing can alter the drug’s release characteristics and increase the risk of side effects.
Yes. Grapefruit juice inhibits CYP3A4, potentially raising ranolazine levels and increasing the risk of QT prolongation. It is best to avoid large amounts of grapefruit or its juice while taking Ranexa.
Many patients experience relief within a few days, but optimal benefit is usually seen after 2-4 weeks of steady dosing and titration.
Since Ranexa is not licensed in the UK, it is generally prescribed under specialist “unlicensed” use and may require prior authorization from the local Clinical Commissioning Group (CCG). Coverage varies by region.
Dose adjustment is recommended for patients with eGFR < 30 mL/min/1.73 m², limiting the total daily dose to 1000 mg. Renal function should be monitored regularly.
Ranolazine works by reducing intracellular calcium overload without changing heart rate or blood pressure, whereas nitrates primarily cause vasodilation and can lead to tolerance with long-term use. This distinct mechanism makes Ranexa a useful option when other agents are insufficient or poorly tolerated.
Ranexa is a brand-name medication whose active ingredient is ranolazine. It belongs to the Heart & Blood Pressure therapeutic class and is formulated as an oral pill. In the United Kingdom Ranexa is not licensed by the MHRA, so it is generally prescribed only under specialist supervision for patients with chronic angina who have not responded to standard therapies. The medication is available in 500 mg and 1000 mg tablet strengths.
Ranolazine acts primarily on the heart’s electrical activity:
The onset of symptom relief is usually observed within a few days, with peak effects reaching steady state after about two weeks of therapy.
Ranolazine is not approved for other cardiac conditions in the UK, and prescribing for any additional indication should follow a careful risk-benefit assessment.
These applications are not approved by the MHRA and should only be undertaken with specialist oversight.
Absolute contraindications
Relative contraindications
These effects are usually mild and transient; they often improve with continued therapy.
If a patient experiences palpitations, fainting, or a markedly prolonged QT interval, urgent medical evaluation is required.
If a dose is missed, take the next dose at the scheduled time; do not double the dose.
This article provides educational information about Ranexa and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
